WO1997025035A1 - Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms - Google Patents

Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms Download PDF

Info

Publication number
WO1997025035A1
WO1997025035A1 PCT/DK1997/000008 DK9700008W WO9725035A1 WO 1997025035 A1 WO1997025035 A1 WO 1997025035A1 DK 9700008 W DK9700008 W DK 9700008W WO 9725035 A1 WO9725035 A1 WO 9725035A1
Authority
WO
WIPO (PCT)
Prior art keywords
use according
com
phenyl
compound
treatment
Prior art date
Application number
PCT/DK1997/000008
Other languages
English (en)
French (fr)
Inventor
Michael Shalmi
Niels Korsgaard
Birgitte Hjort Guldhammer
James Robertson Piggott
Virender Mohan Labroo
Steven Bain
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to AU13672/97A priority Critical patent/AU1367297A/en
Priority to IL12488297A priority patent/IL124882A0/xx
Priority to HU9902683A priority patent/HUP9902683A3/hu
Priority to BR9706967A priority patent/BR9706967A/pt
Priority to EP97900200A priority patent/EP0873120A1/en
Priority to JP9524768A priority patent/JP2000506505A/ja
Publication of WO1997025035A1 publication Critical patent/WO1997025035A1/en
Priority to NO983178A priority patent/NO983178L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Definitions

  • the present invention relates to the use of compounds of the general formula I for the prevention and treatment of menopausal symptoms.
  • the present inventi ⁇ on also embraces pharmaceutical compositions comprising these compounds and methods of using the compounds and their pharmaceutical compositions.
  • the menopause is defined as the final episode of menstrual bleeding in women. However, the term is used commonly to refer to the period of the female climac- teric that encompasses the transitional period between the reproductive years up to and beyond the last episode of menstrual bleeding. This period is also referred to as the peri-menopause or the climacterium. During this period there is a gra ⁇ dual but progressive loss of ovarian function and a variety of endocrine, somatic and psycological changes. The median age of the women at the time of cessati- on of menstrual bleeding is 50 to 51 years. Since the life expectancy of women in developed countries is now close to 80 years, approximately one-third of a woman's life-span occurs after cessation of reproductive function.
  • the symptoms associated with declining estrogen levels in the perimenopause include hot flashes and sweats, atrophic vaginitis, headache, dizziness, joint pain, sleeplessness, apathy, lassitude, muscular weakness, palpitations and psy ⁇ chological symptoms such as changes in mood, depression, memory and concen ⁇ tration deficits, irritability and problems related to sexual functioning. All of these symptoms are a direct consequence of the declining estrogen production.
  • the treatment of these disorders involves different regimens of estro ⁇ gen administration with or without concomitant progestin administration. Estro ⁇ gen alone and in different combinations is often associated with unacceptable side effects.
  • progestin are often poorly tolerated causing depressi- on and may even in some tissues negate the positive results of estrogen.
  • the hormone replacement theraphy often causes unpleasant effects such as water retention, frequently weight gain and prolonged therapy is associated with an in ⁇ creased risk of endometrial cancer.
  • a new compound which ameliorates the symptoms of the menopause, but which is safe and cau- ses less side effects, and preferably brings the woman into a stable post- menopausal state in a reduced period of time than known compounds.
  • Centchroman is a non-steroidal compound known to have antiestrogenic activity. It is in use in India as an oral contraceptive (see, for example, Salman et al., U.S. Patent Specification No. 4,447,622; Singh et al., Acta Endocrinal ( Copenh ) 123 (1992), 444 - 450; Grubb, £un £ ⁇ i ⁇ £bsl ⁇ l Gyo ⁇ cfii 3. ( 1 991 ), 491 - 495; San- karan et al., Contraception 9 ( 1 974), 279 - 289; Indian Patent Specification No. 1 29187).
  • Centchroman has also been investigated as an anti-cancer agent for treatment of advanced breast cancer (Misra et al., Int J Cancer 43 (1 989), 781 - 783. Recently, centchroman as a racemate has been found as a potent choleste ⁇ rol lowering pharmaceutical expressed by a significant decrease of the serum concentrations (S.D. Bain et al., J Min Eon fi£S 2 ( 1 994), S 394).
  • U.S. patent 5,453,442 describes methods of lowering serum cholesterol and in- hibiting smoother muscle cell proliferation in humans and inhibiting uterine fibroid disease and endometriosis in women by administering compounds of formula I as shown therein.
  • US patent 5,280,040 describes methods and phar ⁇ maceutical compositions for reducing bone loss using 3,4-diaryl chromans and their pharmaceutically acceptable salts. There is no disclosure in the patents of using the compounds to treat or prevent menopausal symptoms.
  • One object of the present invention is to provide compounds which can effecti ⁇ vely be used in the treatment or prophylaxis of menopausal symptoms.
  • the present invention is based in part on the discovery that a representative 3,4- diarylchroman, centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta- pyrrolidinoethox ⁇ )phenyl]-7-methoxychroman) is a partial estrogen antago- nist/agonist and elicits similar actions as estrogen in a range of animal models and is useful in the treatment of climacteric symptoms and complaints without having the adverse effects associated with estrogen treatment.
  • compounds of formula I or their pharmaceutically acceptable salts are used for prevention and treatment of menopausal symptoms in a patient.
  • R 1 , R 4 and R 5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C, .6 alkyl, C ⁇ alkoxy or (tertiary amino)(C 1 . 6 alkoxy); and R 2 and
  • R 3 are individually hydrogen or a C 1 -6 alkyl.
  • C ⁇ alkyl includes straight and branched chain alkyl radicals containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-amyl, sec- amyl, n-hexyl, 2-ethylbutyl, 2,3-dimethylbutyl and the like.
  • C, ⁇ al ⁇ koxy includes straight and branched chain alkoxy radicals containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-amyloxy, sec-amyloxy, n-hexyloxy, 2-ethylbutoxy, 2,3- dimethylbutoxy and the like.
  • Hydrogen includes chloro, fluoro, bromo and iodo.
  • (tertiary amino)(C,. 6 alkoxy) is a C,. 6 alkoxy group which is substituted by a tertiary amino radical.
  • the tertiary amino radical may be a N,N- dialkylamine such as a N,N-dimethylamino, N,N-diethylamino, N,N-dipropylamino and N,N-dibutylamino or a polymethyleneimine, e.g., piperidine, pyrrolidine, N- methylpiperazine or morpholine.
  • Preferred compounds include those in which R ' is C,. 6 alkoxy; R 2 and R 3 are C,. 6 alkyl, especially methyl; R 4 is hydrogen; and R 5 is (tertiary amino)(C 1 . 6 alkoxy) of the polymethyleneimine type.
  • R 1 is in the 7-position and is C ⁇ alkoxy, particu ⁇ larly methoxy; each of R 2 and R 3 is methyl, R 4 is hydrogen, and R 5 is in the 4- position and is a (tertiary amino)(C,. 6 alkoxy) radical such as 2-(pyrrolidin-1 - yDethoxy with formula II
  • a particularly preferred compound for use within the present invention is cen ⁇ tchroman having the formula IV
  • 3,4-diarylchromans are prepared according to known methods, such as those di ⁇ sclosed in U.S. Patent Specification No. 3,340,276 to Carney et al., U.S. Patent Specification No. 3,822,287 to Bolger, and Ray et al., Med Chem 12 (1 976), 276 - 279, the contents of which are incorporated herein by reference.
  • Conver ⁇ sion of the cis isomer to the trans configuration by means of an organometallic base-catalyzed rearrangement is disclosed in U.S. Patent Specification No. 3,822,287.
  • the optically active d- and l-enantiomers may be prepared as disclo ⁇ sed by Salman et al.
  • 3,4-diarylchromans of formula I may be prepared in the form of pharmaceutically acceptable salts, especially acid-addition salts, in- eluding salts of organic acids and mineral acids.
  • salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic a- cid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like.
  • Suitable inorga ⁇ nic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids and the like.
  • the acid addition salts may be obtained as the di ⁇ rect products of compound synthesis.
  • the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isola ⁇ ted by evaporating the solvent or otherwise separating the salt and solvent.
  • 3,4-diarylchromans of formula I and their salts are useful within human and vete ⁇ rinary medicine, for example, in the treatment of patients suffering from meno ⁇ pausal symptoms.
  • 3,4-diarylchromans of formula I and their pharmaceutically acceptable salts are formulated with a phar ⁇ maceutically acceptable carrier to provide a medicament for parenteral, oral, na- sal, rectal, subdermal or intradermal or transdermal administration according to conventional methods.
  • Formulations may further include one or more diluents, fillers, emulsifiers, preservatives, buffers, excipients, etc.
  • the active compound of formula I is prepa- red in a form suitable for oral administration, such as a tablet or capsule.
  • a pharmaceutically acceptable salt of the compound of formula I is com ⁇ bined with a carrier and moulded into a tablet.
  • Suitable carriers in this regard in ⁇ clude starch, sugars, dicalcium phosphate, calcium stearate, magnesium stearate and the like.
  • Such compositions may further include one or more auxiliary sub- stances, such as wetting agents, emulsifiers, preservatives, stabilizers, colouring additives, etc.
  • compositions containing a compound of formula I may be admini ⁇ stered one or more times per day or week.
  • An effective amount of such a phar- maceutical composition is the amount that provides a clinically significant effect against menopausal symptoms. Such amounts will depend, in part, on the parti ⁇ cular condition to be treated, age, weight, and general health of the patient, and other factors evident to those skilled in the art.
  • a typical daily dose will contain a nontoxic dosage range of from about 0.001 to about 75 mg/kg patient per day of a compound of the present invention.
  • compositions containing a compound of formula I may be administered in unit dosage form one or more times per day or week.
  • they may be provided as controlled release formulations suitable for dermal implantation.
  • Implants are formulated to provide release of active com ⁇ pound over the desired period of time, which can be up to several years.
  • Con ⁇ trolled-release formulations are disclosed by, for example, Sanders et al., J Pharm Sci 73 ( 1 964), 1 294 - 1 297, 1 984; U.S: Patent Specification No. 4,489,056; and U.S. Patent Specification No. 4,210,644, which are incorpora- ted herein by reference.
  • the following examples are offered by way of illustration, not limitation.
  • Examples of preferred compounds of formula I are centchroman as a racemic mixture and as isolated l-centchroman and d-centchroman enantiomers. Further- more, 3,4-trans-2,2-dimethyl-3-phenyl-4- ⁇ 4-(2-(pyrrolidin-1 -yl)ethoxy)phenyl]-7- hydroxychroman is a preferred compound. The more preferred compound is isola ⁇ ted l-centchroman (l-3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2-(pyrrolidin-1 - yl)ethoxy)phenyl]-7-methoxychroman).
  • Examples of pharmaceutically acceptable acid addition salts are salts with non- toxic acids, either inorganic acids such as hydrochloric acid, sulphuric acid and phosphoric acid, or organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, succinic acid, gluconic acid, lactic acid, citric acid, ascorbic acid, benzoic acid, embonic acid, methanesulphonic acid and malonic acid.
  • inorganic acids such as hydrochloric acid, sulphuric acid and phosphoric acid
  • organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, succinic acid, gluconic acid, lactic acid, citric acid, ascorbic acid, benzoic acid, embonic acid, methanesulphonic acid and malonic acid.
  • a compound of the invention is given in the amount of 0,001 to 75 mg/kg pa ⁇ tient per day and the frequency of vasomotor symptoms are closely monitored together with the variables laid down in the Green Scale or Kupperman Indeks monitoring systems. The dosing of the compound of the invention continues for a period of 4 weeks.
  • This test is ran as Test 1 , except the dosing period is for a period of 6 months.
  • Activity defined as either total cessation of one or more sequellae of the patient, or reduced severity or occurrence thereof, or a more rapid advancement to men ⁇ opausal state, in any of the above assays indicates that the compounds of the invention are useful in the treatment of menopausal symptoms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
PCT/DK1997/000008 1996-01-11 1997-01-09 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms WO1997025035A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU13672/97A AU1367297A (en) 1996-01-11 1997-01-09 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical comp osition for the treatment or prophylaxis of menopausal symptoms
IL12488297A IL124882A0 (en) 1996-01-11 1997-01-09 Use of 3, 4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
HU9902683A HUP9902683A3 (en) 1996-01-11 1997-01-09 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
BR9706967A BR9706967A (pt) 1996-01-11 1997-01-09 Utilização de compostos e processo para tratamento e profilaxia de sintomas relacionados à menopausa
EP97900200A EP0873120A1 (en) 1996-01-11 1997-01-09 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
JP9524768A JP2000506505A (ja) 1996-01-11 1997-01-09 閉経期の症状の治療又は予防のための医薬組成物の製造のための3,4―ジフェニルクロマンの使用
NO983178A NO983178L (no) 1996-01-11 1998-07-10 Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasaytisk preparat for behandling eller profylakse av menopausesymptomer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US983496P 1996-01-11 1996-01-11
US60/009,834 1996-01-11
US67826196A 1996-07-11 1996-07-11
US08/678,261 1996-07-11

Publications (1)

Publication Number Publication Date
WO1997025035A1 true WO1997025035A1 (en) 1997-07-17

Family

ID=26679921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1997/000008 WO1997025035A1 (en) 1996-01-11 1997-01-09 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms

Country Status (12)

Country Link
EP (1) EP0873120A1 (ko)
JP (1) JP2000506505A (ko)
KR (1) KR19990077156A (ko)
AU (1) AU1367297A (ko)
BR (1) BR9706967A (ko)
CA (1) CA2241623A1 (ko)
CZ (1) CZ217298A3 (ko)
HU (1) HUP9902683A3 (ko)
IL (1) IL124882A0 (ko)
NO (1) NO983178L (ko)
PL (1) PL327831A1 (ko)
WO (1) WO1997025035A1 (ko)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
JP2003519219A (ja) * 1999-12-30 2003-06-17 シグナル ファーマシューティカルズ, インコーポレイテッド エストロゲン受容体をモジュレートするための化合物および方法
US7601855B2 (en) 2004-09-21 2009-10-13 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US8389548B2 (en) 1998-06-11 2013-03-05 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
WO2013130832A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
EP2826475A1 (en) 2007-10-16 2015-01-21 Repros Therapeutics Inc. Trans-clomiphene for treating diabetes in hypogonadal men
WO2015135061A1 (en) 2014-03-10 2015-09-17 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
WO2017081171A1 (en) 2015-11-10 2017-05-18 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
US9663484B2 (en) 2010-11-01 2017-05-30 Mei Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
EP3178480A1 (en) 2009-06-16 2017-06-14 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US9701655B2 (en) 2014-02-07 2017-07-11 Novogen Limited Functionalised benzopyran compounds and use thereof
US10980774B2 (en) 2015-02-02 2021-04-20 Mei Pharma, Inc. Combination therapies
US11576891B2 (en) 2010-06-16 2023-02-14 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178862A2 (en) * 1984-10-12 1986-04-23 BCM Technologies, INC. Antiestrogen therapy for symptoms of estrogen deficiency

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178862A2 (en) * 1984-10-12 1986-04-23 BCM Technologies, INC. Antiestrogen therapy for symptoms of estrogen deficiency

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399582A1 (en) 1998-06-11 2011-12-28 Endorecherche Inc. Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
US6670346B1 (en) 1998-06-11 2003-12-30 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8188066B2 (en) 1998-06-11 2012-05-29 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7429576B2 (en) 1998-06-11 2008-09-30 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8389548B2 (en) 1998-06-11 2013-03-05 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7943603B2 (en) 1998-06-11 2011-05-17 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP2386305A2 (en) 1998-06-11 2011-11-16 Endorecherche Inc. Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
EP2386304A2 (en) 1998-06-11 2011-11-16 Endorecherche Inc. Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
JP2003519219A (ja) * 1999-12-30 2003-06-17 シグナル ファーマシューティカルズ, インコーポレイテッド エストロゲン受容体をモジュレートするための化合物および方法
US8461361B2 (en) 2004-09-21 2013-06-11 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US8957109B2 (en) 2004-09-21 2015-02-17 Mei Pharma, Inc. Chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US7601855B2 (en) 2004-09-21 2009-10-13 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
US8084628B2 (en) 2004-09-21 2011-12-27 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
US8697891B2 (en) 2004-09-21 2014-04-15 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
US9381186B2 (en) 2004-09-21 2016-07-05 Mei Pharma, Inc. Substituted chroman derivatives, medicaments and use in therapy
US9198895B2 (en) 2004-09-21 2015-12-01 Mei Pharma, Inc. Chroman derivatives, medicaments and use in therapy
US9138478B2 (en) 2004-09-21 2015-09-22 Mei Pharma, Inc. Substituted chroman derivatives, medicaments and use in therapy
US10478443B2 (en) 2004-10-20 2019-11-19 Endorecherche, Inc. Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US10076525B2 (en) 2004-10-20 2018-09-18 Endorecherche, Inc. Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of dyspareunia in postmenopausal women
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US8629129B2 (en) 2007-08-10 2014-01-14 Endorecherche, Inc. Pharmaceutical compositions
US8957054B2 (en) 2007-08-10 2015-02-17 Endorecherche, Inc. Pharmaceutical compositions
US10881650B2 (en) 2007-08-10 2021-01-05 Endorecherche, Inc. Pharmaceutical compositions
EP2826475A1 (en) 2007-10-16 2015-01-21 Repros Therapeutics Inc. Trans-clomiphene for treating diabetes in hypogonadal men
US10342805B2 (en) 2009-06-16 2019-07-09 Endorecherche, Inc. Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators
EP3682880A1 (en) 2009-06-16 2020-07-22 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US11452731B2 (en) 2009-06-16 2022-09-27 Endorecherche, Inc. Method of treating and preventing loss of cognition
EP3178480A1 (en) 2009-06-16 2017-06-14 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US11576891B2 (en) 2010-06-16 2023-02-14 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US11723893B2 (en) 2010-11-01 2023-08-15 Mei Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
US9708283B2 (en) 2010-11-01 2017-07-18 Mei Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
US11583514B2 (en) 2010-11-01 2023-02-21 Mei Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US9981936B2 (en) 2010-11-01 2018-05-29 Mei Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
US9663484B2 (en) 2010-11-01 2017-05-30 Mei Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US10105346B2 (en) 2010-11-01 2018-10-23 Mei Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US10369132B2 (en) 2010-11-01 2019-08-06 Mei Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
US10973799B2 (en) 2010-11-01 2021-04-13 Mei Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
WO2013130832A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US10370349B2 (en) 2014-02-07 2019-08-06 Kazia Therapeutics Limited Functionalised benzopyran compounds and use thereof
US9701655B2 (en) 2014-02-07 2017-07-11 Novogen Limited Functionalised benzopyran compounds and use thereof
US10548903B2 (en) 2014-03-10 2020-02-04 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
WO2015135061A1 (en) 2014-03-10 2015-09-17 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US10980774B2 (en) 2015-02-02 2021-04-20 Mei Pharma, Inc. Combination therapies
WO2017081171A1 (en) 2015-11-10 2017-05-18 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen

Also Published As

Publication number Publication date
PL327831A1 (en) 1999-01-04
EP0873120A1 (en) 1998-10-28
NO983178L (no) 1998-07-10
HUP9902683A3 (en) 2001-08-28
CZ217298A3 (cs) 1999-01-13
KR19990077156A (ko) 1999-10-25
HUP9902683A2 (hu) 2001-04-28
CA2241623A1 (en) 1997-07-17
IL124882A0 (en) 1999-01-26
JP2000506505A (ja) 2000-05-30
AU1367297A (en) 1997-08-01
BR9706967A (pt) 1999-05-04

Similar Documents

Publication Publication Date Title
US5726202A (en) Benign prostatic hypertrophy
AU693628B2 (en) Use of 3,4-diphenylchromans
WO1997025035A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
EP0873122B1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of prostatic carcinoma
EP0873121A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of atrophy of skin and/or mucous membranes
US6008242A (en) Use of 1-centchroman for the manufacture of a pharmaceutical composition for the treatment of obesity
WO1998033499A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for increasing libido in post-menopausal women
US5886021A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
AU702407B2 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of idiopathic or physiologic gynaecomastia
US5780502A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
EP0921797A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for lowering intraocular pressure
EP0954307A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
WO1998033500A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting senescence-associated motor impairment
WO1998032437A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more psychiatric disorders
MXPA97005219A (en) Use of 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment of profilaxis of disorders ginecologi
KR19980701383A (ko) 부인병 질환의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용(use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of idiopathic or physiologic gynaecomastia)
MXPA97005379A (en) Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for treatment or profilaxis vasodilatad
MXPA97005218A (es) Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis de ginecomastia idiopatica o fisiologica
KR19980701384A (ko) 측발성 또는 생리적 여성형유방의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97191645.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1997900200

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2241623

Country of ref document: CA

Ref document number: 2241623

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/005478

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV1998-2172

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019980705294

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997900200

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-2172

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980705294

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997900200

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-2172

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1019980705294

Country of ref document: KR